| 证券代码：605228 | 证券简称：神通科技 | | --- | --- | | 债券代码：111016 | 债券简称：神通转债 | | | 公告编号：2025-039 | 神通科技集团股份有限公司 关于向不特定对象发行可转换公司债券 2025 年度跟踪评级结果的公告 公司前次主体信用等级为"AA-"，评级展望为"稳定"，"神通转债"债 券信用等级为"AA-"，评级机构为中诚信，评级时间 2024 年 5 月 29 日。 中诚信在对公司经营状况等进行综合分析与评估的基础上，于 2025 年 6 月 17 日出具了《神通科技集团股份有限公司 2025 年度跟踪评级报告》，本次公司 主体信用等级为"AA-"，评级展望为"稳定"；"神通转债"债券信用等级为"AA-"。 本次评级结果较前次没有变化。 本次跟踪评级报告详见公司同日于上海证券交易所网站（www.sse.com.cn） 披露的《神通科技集团股份有限公司 2025 年度跟踪评级报告》。 前次"神通转债"评级：AA-，主体评级：AA-，评级展望：稳定 本次"神通转债"评级：AA-，主体评级：AA-，评级展望：稳定 根据中国证券监督管理委员会《上市公司证券 ...

编号：信评委函字[2025]跟踪 0553 号 神通科技集团股份有限公司 2025 年度跟踪评级报告 声 明 中诚信国际信用评级有限责任公司 2025 年 6 月 17 日 2 神通科技集团股份有限公司 2025 年度跟踪评级报告 本次评级为委托评级，中诚信国际及其评估人员与评级委托方、评级对象不存在任何其他影响本次评级行为独立、 客观、公正的关联关系。 本次评级依据评级对象提供或已经正式对外公布的信息，以及其他根据监管规定收集的信息，中诚信国际按照相关 性、及时性、可靠性的原则对评级信息进行审慎分析，但中诚信国际对于相关信息的合法性、真实性、完整性、准 确性不作任何保证。 中诚信国际及项目人员履行了尽职调查和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的原则。 评级报告的评级结论是中诚信国际依据合理的内部信用评级标准和方法、评级程序做出的独立判断，未受评级委托 方、评级对象和其他第三方的干预和影响。 本评级报告对评级对象信用状况的任何表述和判断仅作为相关决策参考之用，并不意味着中诚信国际实质性建议任 何使用人据此报告采取投资、借贷等交易行为，也不能作为任何人购买、出售或持有相关金融产品的依据。 中 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Core Viewpoint - The company Shentong Technology (605228.SH) announced a plan for its major shareholder, Ningbo Biheng Investment Partnership, to reduce its stake by up to 12,880,640 shares, representing a maximum of 3.00% of the total share capital, due to funding needs [1] Group 1: Shareholder Actions - Ningbo Biheng plans to reduce its holdings through centralized bidding and block trading, with a maximum of 4,293,547 shares (1.00% of total shares) via centralized bidding and 8,587,093 shares (2.00% of total shares) via block trading [1] - The reduction period is set for three months starting from 15 trading days after the announcement [1] Group 2: Shareholding Structure - As of March 31, 2025, Ningbo Biheng is the second-largest shareholder of Shentong Technology, while the controlling shareholder is Ningbo Shentong Investment Co., Ltd. [2] - Ningbo Shentong Investment holds 194,397,178 shares, representing 42.58% of the total shares, with 70,000,000 shares under pledge [2] Group 3: Financial Performance - In Q1 2025, Shentong Technology reported revenue of 342 million yuan, a year-on-year increase of 13.82%, but a net profit attributable to shareholders of 8.93 million yuan, down 22.49% [2] - For the year 2024, the company experienced a revenue decline of 15.22% to 1.389 billion yuan, with a net loss of 31.98 million yuan compared to a profit of 54.77 million yuan in the previous year [2] Group 4: Capital Raising Activities - Shentong Technology went public on January 20, 2021, raising a total of 471 million yuan, with a net amount of 412 million yuan allocated to various expansion and development projects [3] - The company also issued convertible bonds totaling 577 million yuan, with a net amount of approximately 569 million yuan after deducting issuance costs [4][5]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 股东持股的基本情况 神通科技集团股份有限公司（以下简称"公司"）股东宁波必恒创业投资合伙企业（有限合伙）（以下简 称"必恒投资"）持有公司无限售条件流通股64,590,323股，占公司总股本的15.04%（因公司目前处于 2023年限制性股票与股票期权激励计划首次授予股票期权第一个行权期及可转换公司债券转股期，本公 告中的"持股比例"和"计划减持比例"根据公司2025年6月5日总股本429,354,910股计算得出）。上述无限 售条件流通股于2024年1月22日解除限售并上市流通。 ● 减持计划的主要内容 股东必恒投资因自身资金需求，计划通过集中竞价及大宗交易方式减持其持有的公司股份合计不超过 12,880,640股，减持比例不超过公司总股本的3.00%。其中，拟通过集中竞价交易减持公司股份不超过 4,293,547股，即不超过公司总股本的1.00%；拟通过大宗交易减持公司股份不超过8,587,093 ...

| 证券代码：605228 | 证券简称：神通科技 公告编号：2025-038 | | --- | --- | | 债券代码：111016 | 债券简称：神通转债 | 神通科技集团股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 神通科技集团股份有限公司（以下简称"公司"）股东宁波必恒创业投资合伙 企业（有限合伙）（以下简称"必恒投资"）持有公司无限售条件流通股 64,590,323 股，占公司总股本的 15.04%（因公司目前处于 2023 年限制性股票与股票期权激 励计划首次授予股票期权第一个行权期及可转换公司债券转股期，本公告中的 "持股比例"和"计划减持比例"根据公司 2025 年 6 月 5 日总股本 429,354,910 股计算得出）。上述无限售条件流通股于 2024 年 1 月 22 日解除限售并上市流通。 减持计划的主要内容 股东必恒投资因自身资金需求，计划通过集中竞价及大宗交易方式减持其持 有的公司股份合计不超过 12,880, ...

Shareholding Changes - Guotou Chuangye Fund plans to reduce its stake in Huashu Gaoke by up to 2.20%, amounting to a maximum of 9.11 million shares [1] - Biheng Investment intends to reduce its stake in Shentong Technology by up to 3%, totaling a maximum of 12.88 million shares [2] - Guangzhou Chengxin plans to reduce its stake in Jindan Technology by up to 2.93%, which is a maximum of 563.5 thousand shares [3] Regulatory Matters - ST Lutong received an administrative regulatory measure decision from Jiangsu Securities Regulatory Bureau due to internal control deficiencies and failure to disclose significant lawsuits and account freezes [4] - Zhongdian Xinlong confirmed that there are no undisclosed significant matters, despite a stock price fluctuation exceeding 20% over two trading days [5] - Yiming Pharmaceutical stated that there have been no significant changes in its internal and external operating environment, and confirmed the absence of undisclosed significant matters [6]

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets announced significant updates, including changes in control, regulatory measures, and sales performance, which may present investment opportunities and risks for investors [2]. Company Announcements - Zhongying Electronics announced that its controlling shareholder is planning a change in control, leading to a suspension of trading from June 9, 2025, for up to two trading days [3]. - ST Lutong received an administrative regulatory measure from the Jiangsu Securities Regulatory Bureau due to internal control deficiencies and failure to disclose significant lawsuits and account freezes [4]. - Lianhua Technology clarified that it does not directly produce chlorantraniliprole and that the related matters have limited impact on its overall business [5]. - Longshen Rongfa's subsidiary received a CNAS laboratory accreditation certificate, which is expected to positively influence future operations, though it will not significantly impact current performance [6]. Sales Performance - Yisheng Co. reported a significant increase in May sales of breeding pigs, with a total of 10,849 heads sold, representing a year-on-year increase of 207.08% [7]. Shareholding Changes - Shentong Technology's shareholder, Biheng Investment, plans to reduce its stake by up to 3%, equating to a maximum of 12.88 million shares [8]. - Ruoyuchen's shareholder, Langzi Co., intends to reduce its stake by up to 3%, not exceeding 4.7681 million shares [9]. - Oujing Technology's shareholder, Wanzhao Huigu, plans to reduce its stake by up to 3%, equating to a maximum of 5.7722 million shares [10]. - Jindan Technology's shareholder, Guangzhou Chengxin, plans to reduce its stake by up to 2.93%, equating to a maximum of 5.635 million shares [11]. - Huashu Gaoke's shareholder, Guotou Chuangye Fund, plans to reduce its stake by up to 2.2%, equating to a maximum of 9.1117 million shares [12]. - Zhongke Soft's shareholder, Kesuan Chuangyuan, plans to reduce its stake by up to 2%, equating to a maximum of 16.6208 million shares [13]. - Hengrun Co. announced multiple shareholders planning to reduce their stakes, with total reductions not exceeding 1.89% of the company's shares [14]. - Del Shares' shareholder, Wuxu 15 Fund, plans to reduce its stake by up to 1.987%, equating to a maximum of 3 million shares [15]. - Jian Ke Yuan's shareholder, Jian Ke Investment, plans to reduce its stake by up to 1% [17]. - Mindong Electric's shareholder, Fujian Investment Development Group, plans to reduce its stake by up to 1% [18]. - Puli Software's chairman and executives plan to reduce their stakes by a total of up to 0.69% [19].

Group 1 - Zhongying Electronics' controlling shareholder is planning a change in control, leading to a stock suspension starting June 9, 2025, for up to 2 trading days [3] - Lianhua Technology clarified that it does not directly produce chlorantraniliprole, and the related matters have limited impact on the company's overall performance [4] - Longshen Rongfa's subsidiary received CNAS laboratory accreditation, which is expected to positively influence future operations, though it will not significantly impact current performance [5] Group 2 - Yisheng Co. reported May sales of breeding pigs at 10,849 heads, a year-on-year increase of 207.08%, with significant sales increases attributed to delayed orders from April [7] - Shentong Technology's shareholder plans to reduce its stake by up to 3%, amounting to no more than 12.88 million shares [9] - Ruoyuchen's major shareholder intends to reduce its stake by up to 3%, not exceeding 476.81 million shares [10] Group 3 - Oujing Technology's major shareholder plans to reduce its stake by up to 3%, not exceeding 577.22 million shares [12] - Jindan Technology's shareholder plans to reduce its stake by up to 2.93%, amounting to no more than 563.5 million shares [13] - Huashu Gaoke's shareholder intends to reduce its stake by up to 2.2%, not exceeding 911.17 million shares [14] Group 4 - Zhongke Soft's major shareholder plans to reduce its stake by up to 2%, not exceeding 16.62 million shares [15] - Hengrun Co.'s shareholders plan to collectively reduce their stake by up to 1.89%, with specific reductions from various shareholders [16] - Del Shares' shareholder plans to reduce its stake by up to 1.987%, not exceeding 3 million shares [17] Group 5 - Jianke Institute's shareholder plans to reduce its stake by up to 1%, not exceeding 146.66 million shares [18] - Mindong Electric's shareholder plans to reduce its stake by up to 1%, not exceeding 457.95 million shares [19] - Puli Software's chairman and executives plan to collectively reduce their stake by up to 0.69% [20]

(二)股东大会召开的地点：公司会议室（浙江省余姚市兰江街道谭家岭西路 788 号） | 证券代码：605228 | 证券简称：神通科技 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：111016 | 债券简称：神通转债 | | 神通科技集团股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 15 日 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 1、 议案名称：关于 2024 年度董事会工作报告的议案 | 1、出席会议的股东和代理人人数 | 98 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 324,035,015 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 76.6512 | | 份总数的比例（%） | | 审议结果：通过 注：截至本次股东 ...